Abscess
Drug research and approvals for abscess: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 35 studies of abscess are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 35
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting now
Newest start dates first, of 35 recruiting on ClinicalTrials.gov ↗- A Single Dose of Intravenous Penicillin as an Adjunct to Oral Penicillin in the Treatment of Acute Tonsillitis,…NCT07896226 · Phase 4 · Tejs Ehlers Klug · starts Nov 1, 2026
- Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living…NCT07830329 · Phase 2 · Regeneron Pharmaceuticals · starts Oct 29, 2026
- A Study of Amicidin-β Topical Solution for Patients With a Contaminated or Infected Surgical or Traumatic Wound or…NCT07379684 · Phase 1 · Macro Biologics, Inc. · starts Aug 18, 2026
- Evaluation of Non-Surgical Treatment of Breast AbscessNCT07777783 · Not reported · Sohag University · starts Jun 1, 2026
- Biological, Radiographic and Clinical Evaluation of Various Inter-Visit Root Canal Dressings in Retreatment CasesNCT07641933 · Phase 1 · Ain Shams University · starts Jun 1, 2026
- The Impact of Perianal Disease on Patient's Sex LifeNCT07519850 · Not reported · AHEPA University Hospital · starts Mar 31, 2026
- Transthoracic Drainage of Lung Abscesses. A National Randomized Trial.NCT07247461 · Not applicable · University of Aarhus · starts Feb 16, 2026
- Application Effects of Wrist-Ankle Acupuncture in Patients With Different Types of Pain Following Perianal SurgeryNCT07340307 · Not applicable · The Affiliated Hospital of Putian University · starts Oct 25, 2025
- Clearance of Intracranial Blood Products by Continuous Irrigation With the IRRAflow SystemNCT06649097 · Not reported · Christopher P Kellner · starts Sep 25, 2025
- Antibacterial Effects of Intracanal Medicaments in Acute Apical AbscessesNCT07819240 · Not applicable · Ataturk University · starts Sep 15, 2025
Drug pipeline
1 approved, 12 in phase 3, 2 in phase 2; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Clindamycin phosphate
- Alteplase
- Phase 3 Tissue-type plasminogen activator exogenous protein
- Vancomycin
- Phase 3 Peptidoglycan inhibitor
- Fentanyl
- Phase 3 Mu opioid receptor agonist
- Metronidazole
- Phase 3 DNA inhibitor
- Moxifloxacin
- Phase 3 Topoisomerase IV inhibitor
- Sulfamethoxazole
- Phase 3 Bacterial dihydropteroate synthase inhibitor
- Trimethoprim
- Phase 3 Bacterial dihydrofolate reductase inhibitor
- Tazobactam
- Phase 3 Bacterial beta-lactamase TEM inhibitor
- Piperacillin
- Phase 3 Bacterial penicillin-binding protein inhibitor
- Linezolid
- Phase 3 Bacterial 70S ribosome inhibitor
- Oritavancin
- Phase 3 Peptidoglycan inhibitor
- Dalbavancin
- Phase 3 Peptidoglycan inhibitor
- Methylene blue cation
- Phase 2 Reducing agent
- Chlorhexidine
- Phase 2 Cell membrane inhibitor
How its trials ended
155 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 37 whose ending is known, 38% met their primary endpoint, 3% missed it and 59% stopped early.
- Completed, result not reported5837%
- Ongoing4126%
- Status unknown1912%
- Met its primary endpoint149%
- Stopped: other or unclear117%
- Stopped: enrollment or feasibility85%
- Missed its primary endpoint11%
- Stopped: lack of efficacy11%
- Stopped: sponsor or business decision11%
- Stopped: funding11%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA